Assay News and Research

RSS

Aspirin appears to be less effective heart treatment for women than men

A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.

30 Apr 2007

Aspirin therapy for coronary artery disease less effective for women than men

A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.

27 Apr 2007

EPCA-2 testing more accurate way to identify cancer in the prostate

New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year.

27 Apr 2007

Novel two-step mechanism ensures that all cilia beat in unison

Cilia, tiny hair-like structures that propel mucus out of airways, have to agree on the direction of the fluid flow to get things moving. Researchers at the Salk Institute for Biological Studies discovered a novel two-step mechanism that ensures that all cilia beat in unison.

24 Apr 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

New automated test for gene mutations causing fragile X syndrome

A new automated test could enable population screening to identify carriers of the gene mutations causing fragile X syndrome (FXS), the most common inherited form of mental retardation, reports a study in the April issue of Genetics in Medicine, published by the American College of Medical Genetics and Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

19 Apr 2007

New discoveries about stem cells in leukemia, breast and colon cancer

Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. With each new study, scientists are learning more about cancer-initiating properties of stem cells at organ sites and throughout the body.

19 Apr 2007

Nanoparticles could damage DNA and lead to cancer

Tissue studies indicate that nanoparticles, engineered materials about a billionth of a meter in size, could damage DNA and lead to cancer, according to research presented at the 2007 Annual Meeting of the American Association for Cancer Research.

18 Apr 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

FASgen awarded grant for refinement of its serum fatty acid synthase

FASgen has announced that it has been awarded an SBIR grant from National Cancer Institute for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS- Detect ELISA.

10 Apr 2007

Polyphenols versus vitamins as antioxidants

Polyphenols have much better antioxidant properties than vitamins, and have been the object of growing interest on the part of nutritionists, epidemiologists, agrifood firms and consumers over the past decade or so.

30 Mar 2007

Study shows how antibiotic gentamicin affects cystic fibrosis patients with a stop mutation

Genetics tests could help provide cystic fibrosis (CF) patients with targeted treatment in future, pilot study authors suggest.

30 Mar 2007

FDA approves new test for West Nile virus in donors

The U.S. Food and Drug Administration (FDA) has announced the approval of a license supplement for the first fully automated West Nile Virus (WNV) nucleic acid test for donor screening.

4 Mar 2007

FDA clears MammaPrint test for marketing

The Food and Drug Administration (FDA) has cleared for marketing a test that determines the likelihood of breast cancer returning within five to 10 years after a woman's initial cancer. It is the first cleared molecular test that profiles genetic activity.

6 Feb 2007

Odyssey Thera granted U.S. patents for protein-fragment complementation assays

Odyssey Thera announced today that on January 9, 2007, the United States Patent and Trademark Office granted U.S. Patent No. 7,160,691. On January 23, 2007, the USPTO also granted U.S. Patent No. 7,166,424.

5 Feb 2007

Novel approach to synthesizing nanowires

A novel approach to synthesizing nanowires (NWs) allows their direct integration with microelectronic systems for the first time, as well as their ability to act as highly sensitive biomolecule detectors that could revolutionize biological diagnostic applications, according to a report in Nature.

31 Jan 2007

Cruelty-free ELISA for human insulin

In the January issue of Clinical Biochemistry, scientists and physicians with the Physicians Committee for Responsible Medicine (PCRM) outline the method used to develop a cruelty-free ELISA for human insulin that uses monoclonal antibodies produced by cells cultured in an animal-serum-free medium.

30 Jan 2007

A fully integrated microfluidic genetic analysis system with sample-in-answer-out capability

In an accomplishment that represents a significant step toward an era of rapid, inexpensive, bedside testing for cancer, researchers at the University of Virginia have developed a microfluidic device that can process human blood samples and yield diagnostic results within an hour.

8 Jan 2007

Yeast model system may provide a means for treating the earliest stage of Alzheimer's

A century ago this month, German psychiatrist Alois Alzheimer formally described characteristics of the neurodegenerative disease which ultimately came to bear his name. While international efforts to learn about Alzheimer's disease and develop treatments have progressed significantly in recent years, a cure remains an elusive goal.

19 Nov 2006

Modified silicon-based surfaces provide good home to proteins

Silicon, whether in its elemental form as silicon wafers or in its oxidized form, known as silicon dioxide or silica, is proving to be a valuable material for biomedical nanotechnology, in large part because of the biocompatibility and chemical inertness of these substances.

13 Nov 2006